What question did this study set out to answer?

This research aims to evaluate how the market entry of biosimilars affects the pricing strategies and market share of cancer biologics in the US.

Impact of market entry of biosimilars in the US on cancer biologics' pricing strategies, market share, and payer costs.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates changes in cancer biologics pricing and market share post-biosimilar entry, suggesting financial relief for payors.

This research aims to evaluate how the market entry of biosimilars affects the pricing strategies and market share of cancer biologics in the US.
Analyzed MarketScan claims data and Average Sales Price data from Medicare and Medicaid Services.
Calculated quarterly ASP of reference products for cancer versus non-cancer biologics.
Estimated average monthly payor costs before and after biosimilar entry using Healthcare Common Procedure Coding System codes.
The ASP of reference cancer biologics decreased by 4.3% annually post-biosimilar entry, compared to 17.2% for non-cancer biologics.
Market share for cancer biologics decreased by 39.3% for bevacizumab, 34.2% for rituximab, and 35.4% for trastuzumab annually after biosimilar launch.
Monthly payor costs for cancer biologics fell by an average of 45.1%, 52.0%, and 34.6% for bevacizumab, rituximab, and trastuzumab in 2023 compared to before biosimilar entry.

Liu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates changes in cancer biologics pricing and market share post-biosimilar entry, suggesting financial relief for payors.